Intrinsiqq
Atea Pharmaceuticals Inc. logo

Atea Pharmaceuticals Inc.

AVIR

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$318M
EPS-$1.96
P/E-2.02
P/FCF-2.26
EV/EBITDA-0.74
FCF Yield–
Div. Yield–
Net Debt/FCF1.4x
Atea Pharmaceuticals Inc. intrinsic value
52-Week Range
$2.98$6.15

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$155M

▲ +6.0% YoY

Op. Margin

–

ROIC

-61.01%

▼ -9.3pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$141M

▲ +2.6% YoY

Op. Cash Flow (TTM)

-$141M

▲ +2.6% YoY

Net Debt

-$191M

Net Cash Position

Cash & Equiv.

$191M

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with AVIR

CompareIntrinsic value
XERSXeris Biopharma Holdings, Inc.
$16.97+2.11%34
EOLSEvolus Inc.
$6.52-6.86%30
AUPHAurinia Pharmaceuticals Inc.
$14.70-1.28%58
IRWDIronwood Pharmaceuticals Inc.
$4.70-0.21%63
MNKDMannKind Corporation
$3.85-2.53%30
HROWHarrow Inc.
$30.41-5.35%15
SNDXSyndax Pharmaceuticals Inc.
$8.72-4.49%0
ESPREsperion Therapeutics Inc.
No recent price50

Held by ETFs

AVIR is in 13 US ETFs. The largest of them, with AVIR's weight in each:

Atea Pharmaceuticals (AVIR) in three numbers

Quality score
40/100
Best check: revenue growth, 622.5%. Weakest: return on capital, -61.0%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-2.02
Negative: a loss over the last twelve months. Price to free cash flow -2.26.
Financials

Questions about Atea Pharmaceuticals

Is Atea Pharmaceuticals a high-quality business?

Atea Pharmaceuticals scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 622.5%, and its weakest is return on capital at -61.0%. The Quality tab shows every check against its target.

Does Atea Pharmaceuticals (AVIR) pay a dividend?

No. Atea Pharmaceuticals (AVIR) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 8.0% buyback yield. The Dividends tab shows its cash returns.

Source: 10-Q filed 6 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in AVIR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing AVIR

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.